Literature DB >> 17167783

Fas ligand expression in TM4 Sertoli cells is enhanced by estradiol "in situ" production.

Stefania Catalano1, Pietro Rizza, Guowei Gu, Ines Barone, Cinzia Giordano, Stefania Marsico, Ivan Casaburi, Emilia Middea, Marilena Lanzino, Michele Pellegrino, Sebastiano Andò.   

Abstract

The testis is an immunologically privileged site of the body where Sertoli cells work on to favor local immune tolerance by testicular autoantigens segregation and immunosuppressive factors secretion. Fas/Fas Ligand (FasL) system, expressed prevalently in Sertoli cells, has been considered to be one of the central mechanisms in testis immunological homeostasis. In different cell lines it has been reported that the proapoptotic protein FasL is regulated by 17-beta estradiol (E2). Thus, using as experimental model mouse Sertoli cells TM4, which conserve a large spectrum of functional features present in native Sertoli cells, like aromatase activity, we investigated if estradiol "in situ" production may influence FasL expression. Our results demonstrate that an aromatizable androgen like androst-4-ene-3,17-dione (Delta4) enhanced FasL mRNA, protein content and promoter activity in TM4 cells. The treatment with N(6),2'-O-dibutyryladenosine-3'-5'-cyclic monophosphate [(Bu)(2)cAMP] (simulating FSH action), that is well known to stimulate aromatase activity in Sertoli cells, amplified Delta4 induced FasL expression. Functional studies of mutagenesis, electrophoretic mobility shift (EMSA) and chromatin immunoprecipitation (ChIP) assays revealed that the Sp-1 motif on FasL promoter was required for E2 enhanced FasL expression in TM4 cells. These data let us to recruit FasL among those genes whose expression is up-regulated by E2 through a direct interaction of ERalpha with Sp-1 protein. Finally, evidence that an aromatizable androgen is able to increase FasL expression suggests that E2 production by aromatase activity may contribute to maintain the immunoprivilege status of Sertoli cells. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17167783     DOI: 10.1002/jcp.20952

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

1.  Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter.

Authors:  V Bartella; P Rizza; I Barone; D Zito; F Giordano; C Giordano; S Catalano; L Mauro; D Sisci; M L Panno; S A W Fuqua; S Andò
Journal:  Breast Cancer Res Treat       Date:  2012-05-24       Impact factor: 4.872

Review 2.  Tubular fluid secretion in the seminiferous epithelium: ion transporters and aquaporins in Sertoli cells.

Authors:  Luís Rato; Sílvia Socorro; José E B Cavaco; Pedro F Oliveira
Journal:  J Membr Biol       Date:  2010-08-10       Impact factor: 1.843

Review 3.  Estrogens in Male Physiology.

Authors:  Paul S Cooke; Manjunatha K Nanjappa; CheMyong Ko; Gail S Prins; Rex A Hess
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

4.  Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells.

Authors:  Cinzia Giordano; Donatella Vizza; Salvatore Panza; Ines Barone; Daniela Bonofiglio; Marilena Lanzino; Diego Sisci; Francesca De Amicis; Suzanne A W Fuqua; Stefania Catalano; Sebastiano Andò
Journal:  Mol Oncol       Date:  2012-11-23       Impact factor: 6.603

Review 5.  The Leptin Axis and Its Association With the Adaptive Immune System in Breast Cancer.

Authors:  Laura García-Estevez; Silvia González-Martínez; Gema Moreno-Bueno
Journal:  Front Immunol       Date:  2021-11-15       Impact factor: 7.561

6.  DAX-1, as an androgen-target gene, inhibits aromatase expression: a novel mechanism blocking estrogen-dependent breast cancer cell proliferation.

Authors:  M Lanzino; P Maris; R Sirianni; I Barone; I Casaburi; A Chimento; C Giordano; C Morelli; D Sisci; P Rizza; D Bonofiglio; S Catalano; S Andò
Journal:  Cell Death Dis       Date:  2013-07-11       Impact factor: 8.469

7.  Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines.

Authors:  Pietro Rizza; Ines Barone; Domenico Zito; Francesca Giordano; Marilena Lanzino; Francesca De Amicis; Loredana Mauro; Diego Sisci; Stefania Catalano; Karin Dahlman Wright; Jan-Ake Gustafsson; Sebastiano Andò
Journal:  Breast Cancer Res       Date:  2014-02-19       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.